Related Experiment Videos
Ras-dependent oncolysis with an adenovirus VAI mutant
Manel Cascalló1, Gabriel Capellà, Adela Mazo
1Translational Research Laboratory, Institut Català d'Oncologia, 08907, L'Hospitalet, Barcelona, Spain.
Abstract:
Adenovirus synthesize proteins that interact with oncogene and tumor suppressor gene products to set the cell for virus replication. Mutant viruses defective in these functions replicate selectively in cancer cells and represent new tools to treat cancer. We report a selectivity strategy based on deletions of adenovirus Virus-Associated (VA) RNAs. In normal cells, these RNAs are necessary for virus replication because they inactivate the RNA-dependent protein kinase protein kinase R, a kinase that otherwise would block protein translation in response to infection. However, downstream effectors of Ras can also inactivate protein kinase R, and therefore, the need for VA RNA genes should be bypassed in cells with an active Ras pathway. We demonstrate here that a VAI RNA mutant presents a Ras-dependent replication and can be used for oncolytic virotherapy of pancreatic tumors.
Insights
Adenovirus mutant viruses selectively target cancer cells. Deleting Virus-Associated (VA) RNAs enables Ras-dependent replication, offering a new oncolytic virotherapy strategy for pancreatic tumors.
Area of Science:
- Oncolytic virotherapy
- Molecular virology
- Cancer biology
Background:
- Adenoviruses utilize host cell machinery for replication, often interacting with oncogenes and tumor suppressors.
- Mutant adenoviruses engineered for selective replication in cancer cells are promising tools for cancer treatment.
- Adenovirus Virus-Associated (VA) RNAs are crucial for viral replication in normal cells by inhibiting the host protein kinase R (PKR).
Purpose of the Study:
- To develop a novel selectivity strategy for adenovirus-based oncolytic virotherapy.
- To investigate the role of VA RNAs in adenovirus replication and cancer cell targeting.
- To assess the potential of a VAI RNA-deficient adenovirus mutant for treating pancreatic tumors.
Main Methods:
- Engineering adenovirus mutants with deletions in VA RNA genes.
- Evaluating viral replication selectivity in cancer cells versus normal cells.
- Assessing the impact of the Ras signaling pathway on viral replication.
- Testing the efficacy of the VAI RNA mutant in a pancreatic tumor model.
Main Results:
- A VAI RNA mutant adenovirus demonstrated Ras-dependent replication.
- The VAI RNA mutant showed selective replication in cancer cells with an active Ras pathway.
- The VAI RNA mutant proved effective for oncolytic virotherapy of pancreatic tumors.
Conclusions:
- Adenovirus VA RNAs play a critical role in determining viral replication tropism.
- Exploiting the Ras pathway and VA RNA deficiency offers a robust strategy for oncolytic adenovirus development.
- VAI RNA-deficient adenoviruses represent a promising platform for targeted pancreatic cancer virotherapy.